Markets branded prescription medicines in Transplant, Established Medicines, Neuroscience & Oncology.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 708 | 699 | 679 | 763 | 732 | 773 | 763 | 805 |
| Borrowings | 68 | 62 | 24 | 22 | 7 | 5 | 4 | 3 |
| Other Liabilities | 289 | 229 | 242 | 186 | 173 | 158 | 153 | 157 |
| Total Liabilities | 1.1k | 1.0k | 958 | 983 | 925 | 948 | 932 | 978 |
| AssetsFixed Assets | 76 | 64 | 24 | 19 | 7 | 5 | 4 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1.0k | 938 | 934 | 964 | 918 | 943 | 928 | 975 |
| Total Assets | 1.1k | 1.0k | 958 | 983 | 925 | 948 | 932 | 978 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -194 | -23 | -69 | 39 | 45 | 113 | 75 | 47 |
| Cash from Investing | 274 | 56 | 95 | 87 | -153 | 33 | -3 | 18 |
| Cash from Financing | -30 | -41 | -37 | -36 | -30 | -121 | -64 | -64 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -208 | -24 | -69 | 38 | 45 | 113 | 75 | 46 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (18.1×) and current (35.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -3.3% growth and a 18× exit, ₹1389 only delivers your return if you pay ₹243. The price is currently baking in 33% growth.
EPS grows -3.3%/yr for 5 years, then fades to 6% over 2, exits at 18×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -3.3% | 38.30 |
| FY28 | -3.3% | 37.04 |
| FY29 | -3.3% | 35.82 |
| FY30 | -3.3% | 34.63 |
| FY31 | -3.3% | 33.49 |
| FY32 | 1.3% ·fade | 33.94 |
| FY33 | 6.0% ·fade | 35.98 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.